| 李小亮,孙全富,拓飞,等.我国放射诊疗机构131I治疗开展情况与工作人员内照射水平分析[J].中华放射医学与防护杂志,2025,45(6):506-511.Li Xiaoliang,Sun Quanfu,Tuo Fei,et al.Analysis of internal exposure of staff performing 131I treatment in radiodiagnosis and radiotherapy institutions in China[J].Chin J Radiol Med Prot,2025,45(6):506-511 |
| 我国放射诊疗机构131I治疗开展情况与工作人员内照射水平分析 |
| Analysis of internal exposure of staff performing 131I treatment in radiodiagnosis and radiotherapy institutions in China |
| 投稿时间：2024-07-29 |
| DOI：10.3760/cma.j.cn112271-20240729-00286 |
| 中文关键词: 个人监测 内照射 131I 核医学 |
| 英文关键词:Individual monitoring Internal exposure 131I Nuclear medicine |
| 基金项目: |
|
| 摘要点击次数: 13 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的 掌握我国开展131I治疗的放射诊疗机构数和工作人员数量,初步了解131I治疗场所工作人员甲状腺131I水平。方法 通过问卷对2022年我国非军队系统的全部开展核医学项目的医院开展基本情况调查,使用便携式伽玛谱仪对部分碘治疗场所工作人员甲状腺中131I的活度进行测量和分析,并通过全国放射卫生信息平台上报全部结果。结果 截至2022年12月,我国开展临床核医学的医院共有959家,共有工作人员10 820人。开展131I治疗的医院共有623家,占全部核医学医院的65.0%,其中,61.3%的医院配备了131I自动分装仪。开展131I治疗甲状腺癌的医院共有333家,占全部核医学医院的34.7%。2022年共有20个省份对2 210名工作人员进行了内照射监测,有249名(11.3%)工作人员甲状腺131I的活度＞100 Bq,最高值为2.9×104 Bq。4个省份的426人使用高纯锗(HPGe)探测器测量,有101人(23.7%)甲状腺检出131I,有17个省份的1 748人使用碘化钠(NaI)或溴化镧(LaBr)探测器测量,有379人(21.2%)甲状腺检出131I。工作人员131I检出率随所在医院131I购买量的增加而增加,上一年度131I购买量≥3.70 × 106 MBq的医院工作人员131I检出率为32.1%,高于购买量＜3.70×106 MBq的其他3组,且差异有统计学意义(χ2=15.46,P＜0.001)。结论 我国不同省份开展131I治疗的医院数和工作人员数差异较大,碘治疗场所约有1/5人员甲状腺可检出131I。 |
| 英文摘要: |
| Objective To investigate the number of medical institutions and staff involved in 131I diagnosis and therapy in China, and to ascertain the level of 131I activity incorporated in thyroid of medical staff performing the 131I treatment. Methods Questionnaires were used to investigate the basic information on nuclear medicine practices in all the non-military hospitals in China. Portable gamma spectrometers were used to determine and analyze the 131I activity in thyroid of the medical staff in some radioiodine treatment workplaces. The result were reported through National Radiological Health Information Platform. Results Until December 2022, there had been 959 hospitals performing clinical nuclear medicine practices in China, with a total of 10 820 medical staff. In China, there have been 623 hospitals performing 131I therapeutical procedures, accounting for 65.0% of all nuclear medicine hospitals, and 333 hospitals performing 131I treatment of thyroid cancer, accounting for 34.7%. The hospitals equipped with automated radiopharmaceutical dispenser accounted for 61.3% of the 623 hospitals. A total of 2 210 nuclear medicine staff were monitored for internal exposure in 20 provinces in 2022, with 249 (11.3%) having activities above 100 Bq and the maximum value of 2.9 × 104 Bq. A total of 426 nuclear medicine staff in four provinces were detected using HPGe detectors, with 101 (23.7%) detected to have 131I in their thyroid glands. A total of 1 748 in 17 provinces were detected using NaI or LaBr detectors, with 379 (21.2%) detected to have 131I in their thyroid glands. The detection rate of 131I in the staff was found to increase with the increased amount of 131I purchased by hospitals. The detection rate of 131I in the hosptitals having purchased the amount of 131I≥3.70 × 106 MBq in 2021 was 32.1%. This value was notably higher than in the other three groups whose purchased amount ＜3.70 × 106 MBq, with a statistically significant difference(χ2=15.46, P < 0.001). Conclusions There were great differences in the number of both hospitals and staff performing 131I treatment between different provinces in China. About one fifth of the staff in the 131I treatment workplaces could be detected to have incorporated 131I in their thyroid glands. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|